Clinical Scorecard: Intravenous Iloprost Administration at Home Using a Portable Elastomeric Pump for Chronic Limb-Threatening Ischemia: A Preliminary Investigation

At a Glance

Key Highlights

• CLTI is associated with high morbidity and mortality, with 1-year outcome rates exceeding 20% for mortality and major amputation.
• First-line treatment for CLTI includes open or endovascular revascularization, but some patients are not suitable for these procedures.
• Iloprost has been the only pharmacological option for 'no-option' patients for over three decades.
• Different protocols for iloprost infusion may lead to varying outcomes in clinical studies.
• The study aims to evaluate the safety and effectiveness of low-dose iloprost administration at home.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of CLTI requires an ankle pressure ≤ 50 mmHg, clinical symptoms of PAD, and significant stenosis/occlusion confirmed by duplex ultrasound.

Management

• Patients receive a statin plus ezetimibe and a platelet aggregation inhibitor, with rivaroxaban prescribed for eligible patients.

Monitoring & Follow-up

• Patients are followed up at 1, 3, and 6 months, then every 6 months, with DUS performed at each visit.

Risks

• Iloprost-related adverse events and the risk of major amputations are primary concerns.

Patient & Prescribing Data

Patients diagnosed with CLTI who are not candidates for revascularization.

Low-dose intravenous iloprost is administered at home using a portable elastomeric pump.

Clinical Best Practices

• Monitor blood pressure and manage hypertension in patients with CLTI.
• Encourage smoking cessation to improve limb outcomes.
• Assess and manage comorbidities such as diabetes and obesity.

Related Resources & Content

• Clinical Study on Iloprost